Research Article

Assessment of Serum Beta 2-Microglobulin Levels in Crimean-Congo Hemorrhagic Fever Patients: Implications for Immune Activation and Disease Pathogenesis

Volume: 45 Number: 2 June 30, 2024
EN

Assessment of Serum Beta 2-Microglobulin Levels in Crimean-Congo Hemorrhagic Fever Patients: Implications for Immune Activation and Disease Pathogenesis

Abstract

Crimean-Congo Hemorrhagic Fever (CCHF) presents a spectrum of clinical manifestations, ranging from asymptomatic cases to severe, life-threatening conditions. Despite extensive research on CCHF pathogenesis, comprehensive understanding remains elusive. Our investigation focused on assessing serum beta 2-microglobulin (β2M) levels in CCHF patients, aiming to elucidate its potential as an immune activation marker and its involvement in disease pathogenesis. The study enrolled 45 CCHF patients and 45 healthy volunteers as a control group. Serum β2M levels were quantified using the immunoturbidimetric analysis method. The patient group was divided into two groups, mild and moderate-severe, using scoring systems. The mean β2M values for the control, mild, and moderate-severe patient groups were 2.27±0.50, 4.37±1.29, and 5.82±2.62 mg/L, respectively (p<0.001). Positive correlations were noted between β2M concentrations and markers such as BUN, creatinine, uric acid, creatine kinase, and aPTT (p<0.001, r=0.684; p<0.001, r=0.602; p=0.003, r=0.439; p=0.008, r=0.392; p=0.019, r=0.348, respectively). Conversely, negative correlations were observed with total protein, albumin, and platelet count (p=0.021, r=-0.342; p=0.003, r=-0.434; p=0.048, r=-0.296, respectively). The findings suggest a prominent inflammatory response in CCHF, indicated by elevated β2M levels, implying its potential role in the molecular mechanisms of the disease

Keywords

Ethical Statement

The procedures were approved by the Ethical Committee of Sivas Cumhuriyet University following the ethical standards established by the institution (2021-04/02). All procedures were performed in accordance with the Helsinki Declaration as revised in 2013. Informed consent was obtained from all individuals included in this study.

References

  1. [1] Ergönül Ö., Crimean-Congo hemorrhagic fever, Lancet Infect Dis., 6(4) (2006) 203-214.
  2. [2] Adams M.J., Lefkowitz E.J., King A.M., Harrach B., Harrison R.L., Knowles, N.J., et al., Changes to taxonomy and the International Code of Virus Classification and Nomenclature ratified by the International Committee on Taxonomy of Viruses (2017), Arch. Virol, 162(8) (2017) 2505-2538.
  3. [3] Fillâtre P., Revest M., Tattevin P., Crimean-Congo hemorrhagic fever: An update, Med. Mal. Infect, 49(8) (2019) 574-585.
  4. [4] Büyüktuna S.A., Doğan H.O., Diagnosis, Prognosis and Clinical Trial in Crimean-Congo Hemorrhagic Fever. In: Ahmad, S.I. (eds) Human Viruses: Diseases, Treatments and Vaccines. Cham: Springer, (2021) 207–219.
  5. [5] Akıncı E., Bodur H., Leblebicioglu H., Pathogenesis of Crimean-Congo hemorrhagic fever, Vector Borne Zoonotic Dis., 13(7) (2013) 429-437.
  6. [6] Akinci E., Bodur H., Sunbul M., Leblebicioglu H., Prognostic factors, pathophysiology and novel biomarkers in Crimean-Congo hemorrhagic fever, Antiviral Res., 132 (2016) 233-243.
  7. [7] Elaldi N., Kaya S., Crimean-Congo hemorrhagic fever, J Microbiol. Infect Dis., 4(5) (2014) 1-9.
  8. [8] Connolly-Andersen A.M., Moll G., Andersson C., Åkerström S., Karlberg H., Douagi I., et al., Crimean-Congo hemorrhagic fever virus activates endothelial cells, J. Virol, 85(15) (2011) 7766-7774.

Details

Primary Language

English

Subjects

Medical Biochemistry - Proteins, Peptides and Proteomics

Journal Section

Research Article

Publication Date

June 30, 2024

Submission Date

January 19, 2024

Acceptance Date

April 19, 2024

Published in Issue

Year 2024 Volume: 45 Number: 2

APA
Buyuktuna, S. A., Bolat, S., Doğan, K., Çakır, Y., & Dogan, H. O. (2024). Assessment of Serum Beta 2-Microglobulin Levels in Crimean-Congo Hemorrhagic Fever Patients: Implications for Immune Activation and Disease Pathogenesis. Cumhuriyet Science Journal, 45(2), 338-342. https://doi.org/10.17776/csj.1422543

Cited By

As of 2026, Cumhuriyet Science Journal will be published in six issues per year, released in February, April, June, August, October, and December